CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy

• Published in: International journal of antimicrobial agents Vol. 62; no. 1; p. 106817
• Main Authors: Gentile, Ivan, Buonomo, Antonio Riccardo, Corcione, Silvia, Paradiso, Laurenza, Giacobbe, Daniele Roberto, Bavaro, Davide Fiore, Tiseo, Giusy, Sordella, Francesca, Bartoletti, Michele, Palmiero, Giulia, Vozza, Antonietta, Vena, Antonio, Canta, Francesca, Moriello, Nicola Schiano, Congera, Paola, Karruli, Arta, Tascini, Carlo, Viale, Pierluigi, Bono, Valerio Del, Falcone, Marco, Carbonara, Sergio, Mikulska, Malgorzata Karolina, Bassetti, Matteo, Durante-Mangoni, Emanuele, De Rosa, Francesco Giuseppe, Maraolo, Alberto Enrico
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-07-2023
• Subjects: Bloodstream infection; Ceftobiprole; MRSA; Pneumonia; Pneumonia; Bloodstream infection; MRSA; Ceftobiprole
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2023.106817

Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited.
This multi-centre, observational, ambispective investigator-initiated study was undertaken in Italy from January 2018 to December 2019 in order to evaluate the use of ceftobiprole in a real-world setting.
Overall, 195 patients from 10 centres were evaluated (68% retrospectively). Male sex was prevalent (n=121, 62%). Median age was 67 [interquartile range (IQR) 53–75] years. Median Charlson Comorbidity Index score was 5 (IQR 3–7). The most common indication was pneumonia (151/195, 77%), especially HAP. Other uses were skin and soft tissue infections (5%), endocarditis (4%) and bone infections (4%). Ceftobiprole was usually an empiric choice (65%), in combination with other drugs (66%) and as second-line therapy (58%). A causative agent was found in 39% of cases. A diagnosis of sepsis was made in 59 cases (30%). Success in the clinically evaluable population (excluding 12 cases due to isolation of pathogens outside ceftobiprole's spectrum of activity) was obtained in 79% of cases, with all-cause mortality of 20%. On multi-level analysis, three predictors were positively associated with clinical success: male gender, pneumonia and detection of causal agent. Sepsis was a negative predictor. Nine factors were independently associated, favourably or unfavourably, with fatal outcome.
Ceftobiprole is a safe and effective therapeutic choice, even in a real-world setting. More data are needed to establish its efficacy in patients with sepsis.